×
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
NASDAQ:EPZM

Epizyme Stock Forecast, Price & News

$1.48
0.00 (0.00%)
(As of 06/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.46
$1.48
50-Day Range
$0.42
$1.48
52-Week Range
$0.41
$9.51
Volume
10.53 million shs
Average Volume
3.15 million shs
Market Capitalization
$244.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50
30 days | 90 days | 365 days | Advanced Chart

Receive EPZM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Epizyme and its competitors with MarketBeat's FREE daily newsletter.

EPZM Stock Forecast (MarketRank)

Overall MarketRank

2.49 out of 5 stars

Medical Sector

144th out of 1,433 stocks

Pharmaceutical Preparations Industry

52nd out of 685 stocks

Analyst Opinion: 3.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.6 5 -4 -3 -2 -1 -
Epizyme logo

About Epizyme (NASDAQ:EPZM)

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

EPZM Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EPZM
Employees
250
Year Founded
N/A

Company Calendar

Last Earnings
5/10/2022
Today
6/28/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$3.50
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+271.6%
Consensus Rating
Hold
Rating Score (0-4)
2
Research Coverage
5 Analysts

Profitability

Net Income
$-251.12 million
Net Margins
-614.08%
Pretax Margin
-613.94%

Debt

Sales & Book Value

Annual Sales
$37.43 million
Book Value
($0.54) per share

Miscellaneous

Free Float
126,294,000
Market Cap
$244.02 million
Optionable
Optionable
Beta
1.30














Epizyme Frequently Asked Questions

Should I buy or sell Epizyme stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last year. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Epizyme stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EPZM, but not buy additional shares or sell existing shares.
View analyst ratings for Epizyme
or view top-rated stocks.

What is Epizyme's stock price forecast for 2022?

5 Wall Street research analysts have issued 12-month target prices for Epizyme's shares. Their EPZM stock forecasts range from $1.50 to $6.00. On average, they expect Epizyme's share price to reach $3.50 in the next twelve months. This suggests a possible upside of 136.5% from the stock's current price.
View analysts' price targets for Epizyme
or view top-rated stocks among Wall Street analysts.

How has Epizyme's stock performed in 2022?

Epizyme's stock was trading at $2.50 on January 1st, 2022. Since then, EPZM stock has decreased by 40.8% and is now trading at $1.48.
View the best growth stocks for 2022 here
.

When is Epizyme's next earnings date?

Epizyme is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Epizyme
.

How were Epizyme's earnings last quarter?

Epizyme, Inc. (NASDAQ:EPZM) announced its quarterly earnings data on Tuesday, May, 10th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.35) by $0.04. The biopharmaceutical company earned $8.70 million during the quarter, compared to analysts' expectations of $10.86 million. Epizyme had a negative trailing twelve-month return on equity of 2,459.33% and a negative net margin of 614.08%. During the same quarter in the previous year, the firm earned ($0.69) EPS.
View Epizyme's earnings history
.

Who are Epizyme's key executives?

Epizyme's management team includes the following people:
  • Mr. Grant C. Bogle, Pres, CEO, Principal Financial Officer & Director (Age 64, Pay $923.32k)
  • Dr. Jeffery L. Kutok M.D., Ph.D., Chief Scientific Officer (Age 55, Pay $646.13k)
  • Dr. H. Robert Horvitz, Co-Founder & Chairman of the Scientific Advisory Board
  • Dr. Yi Zhang, Scientific Co-Founder & Member of The Scientific Advisory Board
  • Mr. Jerald Korn J.D., Chief Operating Officer (Age 43)
  • Mr. Joseph Beaulieu, Sr. VP, Head of Fin., Controller, Treasurer & Principal Accounting Officer (Age 41) (LinkedIn Profile)
  • Mr. Craig West CFA, VP of Investor Relations
  • Mr. John F. Weidenbruch, Sr. VP, Gen. Counsel & Sec. (Age 61)
  • Ms. Tanja Weber, Chief Bus. Officer
  • Dr. Mark A. De Rosch Ph.D., Chief Regulatory Officer (Age 58)

What other stocks do shareholders of Epizyme own?

What is Epizyme's stock symbol?

Epizyme trades on the NASDAQ under the ticker symbol "EPZM."

Who are Epizyme's major shareholders?

Epizyme's stock is owned by many different institutional and retail investors. Top institutional investors include Primecap Management Co. CA (9.44%), BlackRock Inc. (6.55%), Vanguard Group Inc. (4.53%), Rock Springs Capital Management LP (4.41%), Palo Alto Investors LP (4.12%) and Platinum Investment Management Ltd. (4.01%). Company insiders that own Epizyme stock include Carl Goldfischer, David M Mott, Jeffery Kutok, Joseph Beaulieu, Matthew Ros, Pablo G Legorreta, Paolo Tombesi, Robert B Bazemore, Robert B Bazemore and Shefali Agarwal.
View institutional ownership trends for Epizyme
.

Which institutional investors are selling Epizyme stock?

EPZM stock was sold by a variety of institutional investors in the last quarter, including Jane Street Group LLC, Graham Capital Management L.P., BNP Paribas Arbitrage SA, State Board of Administration of Florida Retirement System, and Group One Trading L.P.. Company insiders that have sold Epizyme company stock in the last two years include Jeffery Kutok, Joseph Beaulieu, Matthew Ros, Paolo Tombesi, Robert B Bazemore, and Shefali Agarwal.
View insider buying and selling activity for Epizyme
or view top insider-selling stocks.

Which institutional investors are buying Epizyme stock?

EPZM stock was purchased by a variety of institutional investors in the last quarter, including Platinum Investment Management Ltd., Rock Springs Capital Management LP, BlackRock Inc., Assenagon Asset Management S.A., Goldman Sachs Group Inc., Bank of America Corp DE, Woodline Partners LP, and Vanguard Group Inc.. Company insiders that have bought Epizyme stock in the last two years include Carl Goldfischer, David M Mott, and Pablo G Legorreta.
View insider buying and selling activity for Epizyme
or or view top insider-buying stocks.

How do I buy shares of Epizyme?

Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Epizyme's stock price today?

One share of EPZM stock can currently be purchased for approximately $1.48.

How much money does Epizyme make?

Epizyme (NASDAQ:EPZM) has a market capitalization of $244.02 million and generates $37.43 million in revenue each year. The biopharmaceutical company earns $-251.12 million in net income (profit) each year or ($2.14) on an earnings per share basis.

How many employees does Epizyme have?

Epizyme employs 250 workers across the globe.

How can I contact Epizyme?

Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The official website for Epizyme is www.epizyme.com. The biopharmaceutical company can be reached via phone at (617) 229-5872, via email at [email protected], or via fax at 617-349-0707.

This page (NASDAQ:EPZM) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.